The hemodynamic effects of 3-adrenergic blockade with bucindolol, a nonselective ,8-antagonist with mild vasodilatory properties, were studied in patients with congestive heart failure. Fifteen patients (New York Heart Association class I-IV) underwent cardiac catheterization before and after 3 months of oral therapy with bucindolol. The left ventricular ejection fraction increased from 0.23+±0.12 to 0.29±0.14 (p=0.007), and end-systolic elastance, a relatively load-independent determinant of contractility, increased from 0.60±0.40 to 1.11±0.45 mm Hg/ml (p =0.0049). Both left ventricular stroke work index (34± 13 to 47±+19 g-m/m2, p=0.0059) and minute work (5.5+2.2 to 7.0+2.6 kg-m/min, p=0.0096) increased despite reductions in left ventricular end-diastolic pressure (19± 8 to 15±5 mm Hg, p =0.021).
small amount of intrinsic sympathomimetic activity has been noted in some in situ model system studies,9'10 this drug appears to have no such intrinsic activity in humans.5"11 Because earlier trials showed beneficial effects of (3-antagonists on ejection fraction, we tested the hypothesis that ,B-adrenergic blockade with bucindolol could improve contractility without increasing myocardial oxygen consumption. We examined bucindolol's effect on left ventricular contractility, myocardial relaxation, chamber stiffness, coronary blood flow, myocardial oxygen consumption, and efficiency.
Methods

Patient Population
Fifteen male patients 32-62 years old (mean+SD, 50±11 years) with clinical congestive heart failure (New York Heart Association [NYHA] class I-IV) and a left ventricular ejection fraction less than 0.45 by radionuclide or contrast angiographic methods within 30 days of entry comprised the study group. To bias the study population toward nonischemic etiology, we entered patients who were suspected of having no coronary artery disease. All patients with a presumptive diagnosis of a dilated cardiomyopathy were approached for entry into the study unless they had a complicating illness. Patients with severe renal (creatinine, >2.5 mg/dl), hepatic (SGOT or SGPT, >3 times that of normal), pulmonary (reactive airways disease), rheumatological (e.g., systemic lupus erythematosus, polyarteritis nodosa, scleroderma, dermatomyositis), or endocrine disease (e.g., primary aldosteronism, pheochromocytoma, hyperthyroidism, hypothyroidism, insulin-dependent diabetes) were excluded. Patients with myocardial infarction within 3 months or constrictive, restrictive, hypertrophic, or primary valvular disease were excluded as were patients with a recent (<3 months) history of ethanol abuse. Myocarditis was ruled out in high-suspicion patients (i.e., patients with <6 months of clinical heart failure of unclear etiology) by endomyocardial biopsy.
All medications were allowed, except l3-adrenergic blocker therapy within 3 months of entry. In addition, angiotensin converting enzyme inhibitors were allowed as long as the dosage remained constant for at least 2 months before entry and unchanged during the study period. All medications remained constant during the study period except for diuretics, which were altered as clinically indicated. Written informed consent was obtained from each patient, and the protocol was approved by the Human Studies Subcommittee of the Dallas Veterans Administration and University of Texas Southwestern Medical Centers.
Hemodynamic Measurement
Each study was performed in the Dallas Veterans Administration Cardiac Catheterization Laboratory. Patients were studied before and after 3 months of oral bucindolol therapy. All patients were studied within 1 week before initiating therapy.
A 7F Wilton-Webster coronary sinus thermodilution catheter and a 7F Simmons II catheter were placed in the coronary sinus for sampling blood for oximetry. Using a femoral approach, a 7F balloontipped thermodilution pulmonary artery catheter was advanced under fluoroscopic guidance to the pulmonary artery. An 8F doublechip Millar (Millar Instruments, Houston, Tex.) micromanometer pigtail catheter was positioned in the left ventricle so one transducer recorded left ventricular pressure while the other transducer recorded simultaneous aortic pressure. This catheter contains a central lumen that allows performance of a left ventriculogram while simultaneous micromanometer pressures are recorded.
Baseline left and right heart pressure recordings were performed before initiation of overdrive atrial (coronary sinus) pacing. These measurements included pulmonary capillary wedge, pulmonary artery, right atrial, aortic, and left ventricular pressures. dP/dt was recorded by electronic differentiation of the simultaneous left ventricular pressure wave form. Recording was made on an optical strip-chart recorder (Honeywell Electronics for Medicine model VR-16) at a paper speed of 100 mm/sec. Thermodilution cardiac outputs were then obtained, and the results of three to five consecutive measurements were averaged. Forward stroke volume was determined by dividing the cardiac output by heart rate. Coronary sinus blood flow measurements were performed with previously established methods,12 and near-simultaneous coronary sinus and arterial blood was sampled for oximetry and determination of myocardial oxygen consumption.13 '4 Ten minutes after initiation of atrial pacing at 15 beats/min above the intrinsic heart rate, left and right heart pressures and cardiac outputs were repeated. This was followed by digital ventriculography with 15-25 ml (total volume) of diluted (60:40) nonionic contrast media (Johexol, Winthrop-Breon Laboratories, New York). Ventriculography was performed at 30 frames/sec with cineradiographic equipment (Philips model Optimus M200, Eindhoven, The Netherlands) interfaced directly to a digital radiographic computer (ADAC, model DPS-4100C, Milpitas, Calif.) and stored as a 512x512x8 bit image matrix. An R wave gated mask was derived from the cardiac cycle before the appearance of radiographic contrast and subtracted from the respective frames containing contrast. During digital ventriculography, simultaneous left ventricular pressures were acquired and stored by the ADAC computer. Left ventriculography was performed in a 300 right anterior oblique projection. Before the first ventriculogram, a standardized grid, at the mid left atrial level, was imaged at the same focal length and image intensifier height as the ventriculograms.
After these measurements were recorded, loading conditions were altered while maintaining atrial pac-ing. Intravenous sodium nitroprusside was initiated at a dose of 0.25-0.50 gug/kg/min and increased by 0.25 ,ug/kg/min every 2-5 minutes to achieve a reduction of 10-20 mm Hg in aortic end-systolic pressure. Care was used to avoid symptomatic hypotension. Repeat simultaneous ventriculograms and hemodynamic recordings were performed at one or two time points after aortic end-systolic pressure had been altered. There was a delay of at least 10 minutes between ventriculograms to allow the left ventricle to return to equilibrium.
After 3 months of therapy, the same procedure was used with care to match the original atrially paced heart rate used in the baseline study.
Selective i was determined using a program developed at the University of Arizona. The micromanometer analog signal from the strip-chart recorder was interfaced with an IBM AT computer equipped with an analog/ digital converter. Approximately 50 beats of the pressure signal was digitized on-line and stored at 200 Hz. The digitized study was subsequently recalled for analysis, and a five-point moving average smoothing routine was then applied. Thus, each cardiac cycle was digitized at a rate of roughly 150-200 points per cardiac cycle, depending on the cycle length. The program automatically identifies end systole, end diastole, peak positive dP/dt, and negative dP/dt for each beat of the acquisition. The decay of left ventricular pressure with time can be closely approximated by the exponential relation21'24:
P=Poe a'+PB where P is left ventricular pressure, P0 is pressure at peak negative dP/dt, t is the time (msec) after peak negative dP/dt, PB is left ventricular asymptote pressure (assuming a nonzero asymptote and assuming that left ventricular pressure decays to infinity), and a is the constant of the exponential relation. The first derivative of this equation with respect to t is: dP/dt = -aPoe aIf P from the first equation is then substituted to eliminate Poe'at: dP/dt= -a(P-PB) Thus, r was calculated using a linear regression of dP/dt versus (P-PB) from maximum negative dP/dt to left ventricular end-diastolic pressure: r= -1/a (the inverse of the slope of the regression). Beats with an r value of less than 0.95 for this linear regression were discarded, and 20-30 beats were analyzed and averaged.
Because r is sensitive to changes in heart rate and afterload,22 the relation of r to aortic end-systolic pressure at matched paced heart rates was examined. 
Results
The clinical characteristics of the 15 patients are summarized in Table 1 . Twelve of the patients had nonischemic etiology for cardiomyopathy, whereas three had significant coronary artery disease to account for their left ventricular dysfunction. Fourteen of the patients were taking angiotensin converting enzyme inhibitors during the trial. None of the patients had a change in angiotensin converting enzyme inhibitor dosage during the trial period or for 2 months before entering the trial. Two of the patients had their diuretic dosage increased nominally during the 3-month trial period (from 80 to 120 mg orally twice daily).
All patients tolerated the titration of bucindolol fractions of less than 0.10, were unable to tolerate the maximal dose of 100 mg twice daily due to mild lightheadedness. One of the three patients was intolerant to even low doses of angiotensin converting enzyme inhibitors due to symptomatic hypotension. A bucindolol dose of 75 mg twice daily was well tolerated in all three of these patients. No other side effects were noted among the 15 patients.
Effect of Bucindolol on Hemodynamics in Absence of Pacing
The changes in hemodynamics can be seen in Table 2 . Heart rates were mildly reduced with bucindolol therapy, but this did not reach statistical significance (82±20 versus 73± 11 min1, p=0.059). There was an increase in cardiac outputs from 5.0±1.5 to 5.8±1.6 1/min (p=0.0043), which can be accounted for by an increase in stroke volumes from 64±25 to 82±28 ml (p=0.0009). The increase in stroke volumes was accompanied by an increase in stroke work (from 34±13 to 47±19 g-m/m2, p=0.0059) and minute work (from 5.5±2.2 to 7.0±2.6 kg-m/min). This occurred despite a decrease in left ventricular end-diastolic pressures from 19±8 to 15+5 mm Hg (p=0.021) (Figure 2 p=NS) ( Table 2 ). Neither myocardial aortocoronary sinus oxygen difference (11.9+1.2 versus 11.6±1.6 vol %, p=NS) nor oxygen extraction changed (68+6% to 65+±6%, p=NS). Despite an increase in stroke work and minute work, myocardial oxygen consumption did not increase (11.6±4.4 to 12.3±4.9 ml 02/min, p=NS). Myocardial efficiency was unchanged after therapy (28+18% versus 30+14%, p=NS). Thus, the increase in mechanical stroke work did not occur at the expense of either oxygen extraction or myocardial efficiency.
Systolic Assessment
Left ventricular volumes. Fourteen of the 15 patients had interpretable ventriculograms, which were obtained during atrial pacing (Table 3) . One patient had ventricular ectopy with each ventriculogram and was excluded from volume and elastance analyses. A significant increase in left ventricular ejection fractions (from 0.23±0.12 to 0.29±0.14,p=0.0071; Figure  3 ) with chronic ,3-adrenergic blocker therapy was due to a decrease in left ventricular end-systolic volumes from 100±51 to 84±51 ml/m2 (p=0.0047) with a smaller decrease in left ventricular end-diastolic volumes from 125±48 to 111±52 ml/m2 (p=0.041). The decrease in left ventricular end-systolic volumes and increase in ejection fractions occurred despite decreased left ventricular end-diastolic pressures and volumes (preload) and increased aortic end-systolic pressures (afterload). This suggests increased myocardial contractility. Ejection fractions in the patients without (n =11) coronary heart disease also increased significantly (p<0.025) (Figure 3) .
Isovolumic indexes of contractility. At matched paced heart rates without correction for end-diastolic volume, peak +dP/dt increased from 895±172 to 1,055±265 mmHg/sec (p=0.014) after bucindolol therapy. To correct for changes in end-diastolic volumes, we examined the relation of peak +dP/dt to left ventricular end-diastolic volume at matched paced heart rates. This relatively load-independent index of contractilityl8 exhibited a significant upward shift of the relation between +dP/dt and preload with bucin- (Figure 4) indicating that the drug improved contractility (p=0.0005).
End-systolic elastance. An example of Bes before and after bucindolol is shown in Figure 1 . As is evident in this example, the slope of the end-systolic pressure-volume relation was markedly increased by chronic p-blockade with bucindolol. This suggests an increase in myocardial contractility in this patient. Ees was determined in 12 of the 15 patients (Figure 3 Diastolic Assessment Left ventricular isovolumic relaxation. At the prepacing heart rate, there was no difference in r after bucindolol therapy (96+17 versus 99+19 msec, p=0.67), despite an increase in end-systolic pressure. However, at a higher paced heart rate, there was a significant reduction in r (92±17 versus 73 + 11 msec, p=0.0013; Figure 5 ), suggesting improved relaxation with bucindolol therapy. To correct for the effects of end-systolic pressure and heart rate on r, the relation of X to left ventricular end-systolic pressure at matched heart rates, before and after bucindolol therapy, was examined ( Figure 5 ). There was a significant downward shift in this relation after bucindolol (p=0.014), suggesting improved myocardial relaxation.
Maximum -dP/dt increased from 946±+193 to 1,125 ±373 mm Hg/sec at matched paced heart rates (p=0.027). This increase in maximum -dP/dt occurred despite a decrease in preload. This also suggests improved myocardial relaxation.
Left ventricular pressure-volume relation. The relation of the left ventricular end-diastolic pressure to volume and the changes in chamber stiffness constant (k) are shown in Figure 6 . As is evident, there was no significant alteration in the left ventricular pressurevolume relation after bucindolol therapy. Both pressure and volume were decreased along a common curve rather than shifting curves (Figure 6a ). The slope (k) of the logarithm of left ventricular enddiastolic pressure-left ventricular end-diastolic volume relation was 0.020+0.026 ml-l before therapy and 0.013±0.010 ml-l (p=0.51) after bucindolol ( Figure 6b ). As the intercept of this relation was also unchanged after therapy, this does not represent a parallel shift of this relation. 
Discussion
Hemodynamic Benefit In this study, ,B-adrenergic blockade with bucindolol improved two relatively load-independent indexes of contractility-the end-systolic pressure-volume relation and the peak +dP/dt-end-diastolic volume relation. In addition, stroke work increased at a lower left ventricular end-diastolic pressure, and left ventricular end-systolic volume was reduced at a similar end-systolic pressure. An increase in left ventricular ejection fraction with 3-adrenergic blockade in patients with chronic congestive heart failure has been shown previously.1,4-7 However, ejection fraction is sensitive to loading conditions and does not necessarily reflect myocardial contractility. The present study suggests that chronic P-blockade may improve myocardial contractility in patients with congestive heart failure.
Myocardial relaxation also appeared to improve after long-term bucindolol therapy as evidenced by 24 an increase in -dP/dt at matched heart rates but lower preloads. The reduction in r at matched heart rates and afterload cannot be accounted for by a decrease in preload, to which T is relatively insensitive. 23 The lack of a decrease in r at the baseline heart rate may reflect unmatched afterload and heart rate. Previous investigators have shown that f,-agonists given acutely will shift the r-end-systolic pressure relation downward in both normal and failing hearts, whereas ,B-blockers shift the relation upward.22'27 The ability of chronic administration of p-adrenergic blockade to produce the opposite effect in congestive heart failure (i.e., to improve relaxation) is unexpected. There was no significant alteration in the left ventricular pressure-volume relation after bucindolol therapy. Both pressure and volume were concomitantly decreased after /3-adrenergic blockade along a common curve rather than shifting curves. Right panel: Change in the chamber stiffness constant (k) with 13-adrenergic blockade. As can be seen, k was unchanged after bucindolol therapy. Because the intercept of this relation was also unchanged after therapy, this does not represent a parallel shift of this relation.
seen with p-blocker administration in congestive heart failure in one previous study.28 Possible explanations for these differences between acute and chronic P-adrenergic blockade include presence of chamber remodeling and collagen production over time, which could offset reductions in myocardial elastic stiffness; an increase in coronary vascular volume, which could offset a decrement in myocardial stiffness; or transient alterations in myocardial elastic stiffness, which are not found with longer administration.
Energetic considerations. There is evidence in both patients and animal models of heart failure that the failing heart is in an energy-depleted state. [29] [30] [31] [32] [33] Although the unexpected improvement in both contractility and relaxation after chronic administration of bucindolol could have arisen from favorable effects on myocardial energetics, direct measurements of myocardial high-energy phosphate reserves would be needed to establish such a mechanism. Nevertheless, bucindolol increased stroke work without a significant increase in oxygen consumption or decrease in afterload. The The use of a p-adrenergic blocker with mild intrinsic sympathomimetic activity in some in situ model systems9"10 raises the possibility that inotropic stimulation, rather than p-blockade, increased contractility in the present study. However, no intrinsic sympathomimetic activity in humans has been demonstrated.5,8"1' Furthermore, evidence that bucindolol has p3-blocking properties equipotent to those of propanolol5'9"1' and that bucindolol reduced heart rate by about 10% in these patients suggests that the predominant effect of bucindolol is 8-blockade and not P stimulation.
Although bucindolol has weak a,-antagonist properties (the affinity of bucindolol for myocardial a,-receptors is approximately 30-fold less than that for p-adrenergic receptors) and some direct vasodilating effects," this cannot be considered its primary mode of action. There was a small decrease in systemic vascular resistance in our study, but this was not statistically significant. The increase in systolic elastance and load-corrected peak +dP/dt suggests the major effect is on contractility and not afterload reduction.
Theoretical considerations. The present study suggests that myocardial contractility and relaxation improve with chronic p-adrenergic blocker therapy and that mechanical work increases without concomitant increases in oxygen consumption. These data imply that bucindolol is energetically favorable. The mechanism by which bucindolol improves myocardial contractility and relaxation is uncertain and beyond the scope of this hemodynamic study. However, several mechanisms have been postulated. [4] [5] [6] 39, 40 Animal and human data suggest that high concentrations of systemic catecholamines induce myocardial necrosis and dysfunction, [41] [42] [43] 
